Recently, chronic administration of the dual GIP and GLP-1 receptor agonist in mice with diet-induced obesity potently decreased body weight and appetite, and these effects were significantly greater compared to that with GLP-1 receptor agonist treatment alone [9]. Here, GLP1R is linked to obesity disorder.